TABLE 1.
Patient characteristics
Study population | Group A (n = 8) | Group B (n = 7) | P values | |
---|---|---|---|---|
(n = 15) | Start exercise | Start control | Group A vs B | |
Female, n (%) | 6 (40) | 3 (37.5) | 3 (43) | 0.85 |
Age, y | 15 [12 to 16] | 15.5 [14.3 to 16.0] | 12 [9 to 15] | 0.07 |
Age at diagnosis, y | 9.5 (4.0) | 10.9 (4.2) | 7.9 (3.3) | 0.15 |
Height for age, SDS | −0.23 [−1.95 to 0.7] | −0.19 [−0.98 to 0.65] | −0.65 [−0.95 to 0.7] | 1.00 |
Weight for height, SDS | 0.95 [0.1 to 3.19] | 1.52 [0.37 to 3.39] | 0.21 [−0.38 to 0.95] | 0.04 * |
BMI, kg/m 2 | 20.4 [17.5 to 31.5] | 24.0 [18.5 to 32.4] | 17.5 [16.3 to 22.3] | 0.07 |
Disease type (%) | ||||
Ulcerative colitis | 5 (33.3) | 1 (12.5) | 4 (57) | 0.07 |
Crohn disease | 10 (66.7) | 7 (87.5) | 3 (43) | |
Extra intestinal manifestation (%) | ||||
Arthralgia/arthritis | 3 (20) | 2 (25) | 1 (14.3) | |
Primary sclerosing cholangitis | 2 (13) | 1 (12.5) | 1 (14.3) | |
Active perianal fistulae | 1 (6.7) | 1 (12.5) | 0 | |
COVID-19 positive during study (%) | 1 (6.7) | 0 | 1 (14.3) | |
PCDAI + PUCAI | 15 [2.5 to 22.5] | 10 [0.63 to 20.6] | 15 [5 to 30] | 0.08 |
Maintenance treatment, n (%) | ||||
Aminosalicylates | 4 (26.6) | 3 (37.5) | 1 (12.5) | |
Immunomodulators | 10 (66.7) | 4 (50) | 6 (85.7) | |
Biologicals | 10 (66.7) | 5 (62.5) | 5 (71.4) | |
Corticosteroids | 0 | 0 | 01 | |
No medication | 0 | 0 | 0 |
Values are shown in mean ± SD or as median [IQR]. P values were measured using paired t testing (parametric data) or Wilcoxon rank sum test (nonparametric data). Difference between Group A and B were calculated using the Chi-square test or Fisher exact test. 1: One patient in group B received prednisolone during the exercise intervention, Supplement 2, Supplemental Digital Content, http://links.lww.com/MPG/D157 shows detailed medication descriptions including doses.
BMI = body weight index; PCDAI = Pediatric Crohn Disease Activity Index; PUCAI = Pediatric Ulcerative Colitis Activity Index; SDS = standard deviation score; vs = versus.
P < 0.05.